Ligand Pharmaceuticals (LGND)
(Delayed Data from NSDQ)
$84.26 USD
+1.93 (2.34%)
Updated Jun 28, 2024 04:00 PM ET
After-Market: $83.40 -0.86 (-1.02%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$84.26 USD
+1.93 (2.34%)
Updated Jun 28, 2024 04:00 PM ET
After-Market: $83.40 -0.86 (-1.02%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
LGND or ILMN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
LGND vs. ILMN: Which Stock Is the Better Value Option?
Prothena (PRTA) Alzheimer's Disease Drug Licensed by BMY
by Zacks Equity Research
Prothena (PRTA) will receive $55 million from Bristol Myers Squibb for an exclusive worldwide license to PRX005, designed for the potential treatment of Alzheimer's disease.
Bausch Health (BHC) Secures $600M Financing Facility, Stock Up
by Zacks Equity Research
Bausch (BHC) enters into a $600 million non-recourse financing facility with KKR to boost liquidity.
Novartis (NVS) Entresto Patent Faces Setback, Stock Down
by Zacks Equity Research
Novartis (NVS) faces a setback in the patent litigation with respect to the blockbuster heart disease drug Entresto. Shares decline.
Factors That Make Universal Health (UHS) an Attractive Bet Now
by Zacks Equity Research
Universal Health (UHS) remains well-poised for growth on the resumption of elective surgeries, a diversified treatment network and solid cash reserves.
Caribou Biosciences (CRBU) Soars on $25M Investment by Pfizer
by Zacks Equity Research
Caribou Biosciences (CRBU) gets a major boost with a $25 million equity investment by Pfizer, which will accelerate the development of its allogeneic CAR-T cell therapy pipeline.
Amneal (AMRX) Shares Down on CRL for Parkinson's Disease Drug
by Zacks Equity Research
Amneal (AMRX) suffers a setback as the FDA issues a complete response letter (CRL) to its new drug application (NDA) for IPX203 for treating Parkinson's disease.
Novartis (NVS) to Divest Xiidra, SAF312 to Streamline Focus
by Zacks Equity Research
Novartis (NVS) signs a deal to divest Xiidra and SAF312 (libvatrep) to Bausch + Lomb for $2.5 billion.
Roche (RHHBY) Announces Positive Long-Term Data on SMA Drug
by Zacks Equity Research
Roche's (RHHBY) SMA drug Evrysdi maintains its efficacy and safety profile in children with type 1 SMA after four years of treatment.
Bristol Myers' (BMY) Opdivo With Chemo Gets EC Nod for NSCLC
by Zacks Equity Research
Bristol Myers' (BMY) Opdivo, in combination with chemotherapy, gains European Commission approval for neoadjuvant treatment of non-small cell lung cancer, offering new hope for reducing recurrence risk.
3 Stocks to Buy on New Analyst Coverage
by Shrabana Mukherjee
The recent surge in analyst coverage for stocks such as Ligand (LGND), Ambac (AMBC) and Exponent (EXPO) indicates the potential for significant price appreciation in the near term.
Sanofi (SNY) Atopic Dermatitis Drug Meets Goals in Phase II Study
by Zacks Equity Research
Sanofi's (SNY) phase II study, investigating amlitelimab for moderate-to-severe atopic dermatitis in adults, meets the primary endpoint.
Find Stocks to Buy in July that are Gaining More Attention on Wall Street
by Benjamin Rains
Here is how to use our new analyst coverage screen to help investors find stocks to buy in July and for the second half of 2023.
FibroGen (FGEN) Plunges on Failure of Late-Stage IPF Study
by Zacks Equity Research
FibroGen (FGEN) plummets on yet another pipeline setback. The phase III study, ZEPHYRUS-1, evaluating the safety and efficacy of pamrevlumab in patients with idiopathic pulmonary fibrosis fails to meet goals.
Bristol Myers (BMY) Heart Drug Camzyos Wins EC Approval
by Zacks Equity Research
Bristol Myers (BMY) receives EC approval for Camzyos for treating symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy (HCM) in adult patients.
GSK's (GSK) Gonorrhoea Vaccine Gets FDA Fast Track Tag
by Zacks Equity Research
The FDA grants fast-track designation to GSK's investigational gonorrhoeae vaccine candidate. The grant enables GSK to seek expedited review for a potential FDA filing of the vaccine.
Here's Why You Should Retain Molina (MOH) in Your Portfolio
by Zacks Equity Research
Numerous contract wins, financial flexibility and strong performing Medicaid and Medicare segments poise Molina (MOH) well for growth.
Intercept (ICPT) to Restructure Operations, Cut Workforce
by Zacks Equity Research
Intercept (ICPT) looks to restructure operations, discontinue all NASH-related investments and reduce its workforce by one-third.
Gilead (GILD) Breast Cancer Drug Gets Positive CHMP Opinion
by Zacks Equity Research
Gilead's breast cancer drug Trodelvy gets positive CHMP opinion for a second indication in Europe.
Is GSK PLC Sponsored ADR (GSK) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how GSK (GSK) and Ligand Pharmaceuticals (LGND) have performed compared to their sector so far this year.
Gilead Sciences (GILD) Announces Positive HDV Treatment Data
by Zacks Equity Research
Gilead Sciences, Inc. (GILD) announces data on Hepcludex that reinforces the potential of bulevirtide as an effective and well-tolerated treatment for chronic HDV after 96 weeks.
Humana's (HUM) CenterWell Unit Plans to Expand in Tennessee
by Zacks Equity Research
Humana's (HUM) CenterWell business is likely to benefit from its promising plans to expand across middle Tennessee this year.
Intercept (ICPT) NDA for NASH Treatment Gets CRL From FDA
by Zacks Equity Research
Intercept's (ICPT) NDA for obeticholic acid (OCA) gets a complete response letter (CRL) from the FDA for treating pre-cirrhotic fibrosis due to nonalcoholic steatohepatitis (NASH).
LGND vs. ILMN: Which Stock Is the Better Value Option?
by Zacks Equity Research
LGND vs. ILMN: Which Stock Is the Better Value Option?
bluebird's (BLUE) Gene Therapy for SCD Gets Priority Review
by Zacks Equity Research
bluebird's (BLUE) gene therapy lovotibeglogene autotemcel gets Priority Review in the United States for sickle cell disease.